U.S. Markets closed

Blog Coverage Second Sight Wins Reimbursement Approval for Argus II Retinal Prosthesis System

Upcoming AWS Coverage on STERIS Post-Earnings Results

LONDON, UK / ACCESSWIRE / February 3, 2017 / Active Wall St. blog coverage looks at the headline from Second Sight Medical Products, Inc. (NASDAQ: EYES) as the Company announced on February 02, 2017, that the German Institute for the Hospital Remuneration System has provided its full approval for the Epiretinal Prosthesis across 15 hospitals under the NUB1 innovation program. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.

One of Second Sight Medical Products' competitors within the Medical Appliances & Equipment space, STERIS PLC (NYSE: STE), announced on January 23, 2017, that it will conduct a conference call to discuss its Q3 FY17 financial results at 10:00 a.m. ET on Tuesday, February 07, 2017. AWS will be initiating a research report on STERIS in the coming days.

Today, AWS is promoting its blog coverage on EYES; touching on STE. Get all of our free blog coverage and more by clicking on the link below:



The Decision

This decision allows approved hospitals to negotiate reimbursement coverage for treating patients with advanced stage Retinitis Pigmentosa (RP) with the Argus® II Retinal Prosthesis system, with statutory health insurance companies that covers more than 85% of German population. A NUB decision is valid for one year and can be renewed by application.

In Europe, Argus II is indicated for blind people suffering from advanced outer retinal degenerative diseases such as RP. RP is an inherited disease that often results in nearly complete blindness, affecting up to 30,000 Germans and 167,000 Europeans.

"This NUB renewal is a significant endorsement of the strong interest of German ophthalmologists to help blind patients restore some of their vision. We look forward to collaborating with leaders in the ophthalmic and patient community who are committed to help patients living with blindness as a result of severe diseases such as Retinitis Pigmentosa," said Will McGuire, President and CEO of Second Sight Medical Products.

What is Argus II® Retinal Prosthesis System?

Second Sight's Argus II System provides electrical stimulation that bypasses the defunct retinal cells and stimulates remaining viable cells inducing visual perception in individuals with severe to profound Retinitis Pigmentosa. The Argus II works by converting images captured by a miniature video camera mounted on the patient's glasses into a series of small electrical pulses, which are transmitted wirelessly to an array of electrodes implanted on the surface of the retina. These pulses are intended to stimulate the retina's remaining cells, resulting in the perception of patterns of light in the brain. The patient then learns to interpret these visual patterns, thereby regaining some visual function. The Argus II is the first artificial retina to receive widespread approval, and is offered at approved centers in Canada, France, Germany, Italy, Netherlands, Saudi Arabia, Spain, Switzerland, Turkey, UK, and the US.

Follows UK Proposal

On December 22nd, 2016, Second Sight announced that following a positive recommendation from advisors to the UK Government's healthcare funding authority for specialized services in England that, for the first time in the UK, the publicly-funded NHS system will fund blind patients with RP to receive treatment with the Argus® II Retinal Prosthesis System (Argus II) "bionic eye".

NHS England has announced that a selective group of severely blind patients with Retinitis Pigmentosa can have access to Argus II. There will be two implantation centers: The Manchester Royal Eye Hospital in the north of England, and in the south, London's Moorfields Eye Hospital. The hospitals and Second Sight will also provide follow up, rehabilitation and support to patients receiving an Argus II implant.

Argus II will be funded via the Commissioning through Evaluation (CtE) program. The CtE program is especially designed for treatments that show significant promise for the future, while new clinical and patient experience data are collected within a formal evaluation program. Argus II is already reimbursed under a similar "coverage with evidence development" program in France called "Forfait Innovation".

Stock Performance

At the close of trading session on Thursday, February 02, 2017, following the announcement, Second Sight Medical Products' stock price climbed 4.08% to end the day at $1.53. A total volume of 525.12 thousand shares were exchanged during the session, which was above the 3-month average volume of 320.58 thousand shares. The stock currently has a market cap of $64.58 million.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street